Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition
Our results suggest switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline in NPZ-12 and in specific domains was observed.
Authors
- Carmela Pinnetti (ORCID: https://orcid.org/0000-0003-1350-4032)
- Giulia Del Duca (ORCID: https://orcid.org/0009-0004-3408-3817)
- Rita Bellagamba
- Roberta Gagliardini (ORCID: https://orcid.org/0000-0002-6351-2623)
- Jessica Paulicelli (ORCID: https://orcid.org/0009-0008-8361-9605)
- Maria Maddalena Plazzi (ORCID: https://orcid.org/0000-0002-1574-1552)
- Andrea Antinori (ORCID: https://orcid.org/0000-0003-2121-4684)
- Rozenn Esvan (ORCID: https://orcid.org/0000-0001-6127-0045)
- Federico De Zottis (ORCID: https://orcid.org/0000-0001-9040-2000)
- Alessandra Vergori (ORCID: https://orcid.org/0000-0001-6944-0686)
- Marisa Fusto
- Valentina Mazzotta (ORCID: https://orcid.org/0000-0002-0240-7504)
- Patrizia Lorenzini (ORCID: https://orcid.org/0000-0002-4629-2067)
- Ilaria Mastrorosa (ORCID: https://orcid.org/0000-0003-1944-662X)
- Marta Camici (ORCID: https://orcid.org/0000-0002-6624-7917)
- Anna Clelia Brita
- Elisabetta Grilli
- Sandrine Ottou
Institutions
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- National Centre for Disease Prevention and Control (IT)
Publication Details
- Journal
- AIDS
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1097/qad.0000000000004043
- Citations
- 3
- Primary Topic
- Microfinance and Financial Inclusion
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- ViiV Healthcare
- Mylan
- Moderna
- Cilag